Clinicians now face the challenge of guiding their patients with type 2 diabetes in whether to add SGLT-2 inhibitors, GLP-1 receptor agonists, or finerenone and tirzepatide to their ongoing therapeutic regimens. Here, GLP1R is linked to type 2 diabetes mellitus.